|1||NCT01900600||Active, not recruiting||Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)||
||Other / Industry||
||16||All||18 Years to 110 Years (Adult, Senior)||NCT01900600||HM13782
|April 2013||November 2018||November 2018||July 16, 2013||September 15, 2017||
|2||NCT01327846||Active, not recruiting||Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)||
||10061||All||18 Years and older (Adult, Senior)||NCT01327846||CACZ885M2301
|CANTOS||April 11, 2011||March 28, 2017||March 2, 2020||April 4, 2011||March 20, 2018||
† Study has passed its completion date and status has not been verified in more than two years.